Add to ORKGPurpose: Rituximab is a chimeric anti-CD20 monoclonal anti-body. We aimed to explore the safety and tolerability of rapid infusion rituximab, (over 90 minutes) in patients with non-Hodg
The anti-CD20 monoclonal antibody rituximab (MabThera®/Rituxan®) has been proven to improve outcomes...
The goal of this study was to approach a global clinical issue that is imperative using an evidence-...
The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c....
Rituximab (Mabthera®) is currently approved for the treatment of multiple subtypes of CD20-expressin...
Background: Rituximab is a monoclonal antibody directed against CD20, a pan B lymphocyte marker. It ...
Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent c...
The purpose of this study is to critically appraise, synthesize and present the best available evide...
Copyright © 2013 Masahiro Yokoyama et al. This is an open access article distributed under the Creat...
The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the trea...
monoclonal antibody for the treatment of cancer. Rituximab, an anti-CD20 chimeric monoclonal anti-bo...
Purpose: Off-label prescribing in oncology is common and unregulated. The aim of this study was to d...
International audienceTreatment with rituximab has improved the outcome for patients with non-Hodgki...
Because of its B-cell depleting effect, rituximab has entered clinical trials in several autoimmune ...
Rituximab is a human/mouse chimeric monoclonal antibody that binds to the CD20 antigen and is expres...
Rituximab is a human/mouse chimeric monoclonal antibody that binds to the CD20 antigen and is expres...
The anti-CD20 monoclonal antibody rituximab (MabThera®/Rituxan®) has been proven to improve outcomes...
The goal of this study was to approach a global clinical issue that is imperative using an evidence-...
The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c....
Rituximab (Mabthera®) is currently approved for the treatment of multiple subtypes of CD20-expressin...
Background: Rituximab is a monoclonal antibody directed against CD20, a pan B lymphocyte marker. It ...
Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent c...
The purpose of this study is to critically appraise, synthesize and present the best available evide...
Copyright © 2013 Masahiro Yokoyama et al. This is an open access article distributed under the Creat...
The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the trea...
monoclonal antibody for the treatment of cancer. Rituximab, an anti-CD20 chimeric monoclonal anti-bo...
Purpose: Off-label prescribing in oncology is common and unregulated. The aim of this study was to d...
International audienceTreatment with rituximab has improved the outcome for patients with non-Hodgki...
Because of its B-cell depleting effect, rituximab has entered clinical trials in several autoimmune ...
Rituximab is a human/mouse chimeric monoclonal antibody that binds to the CD20 antigen and is expres...
Rituximab is a human/mouse chimeric monoclonal antibody that binds to the CD20 antigen and is expres...
The anti-CD20 monoclonal antibody rituximab (MabThera®/Rituxan®) has been proven to improve outcomes...
The goal of this study was to approach a global clinical issue that is imperative using an evidence-...
The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c....